Human serum albumin nanoparticles for ocular delivery of bevacizumab

Redín, Inés Luis de; Boiero, Carolina; Martínez-Ohárriz, María Cristina; Agüeros, Maite; Ramos, Rocío; Peñuelas, Iván; Allemandi, Daniel Alberto; Llabot, Juan Manuel; Irache, Juan M.

doi:10.1016/j.ijpharm.2018.02.003

Cited by 60 publications

(44 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Trehalose has been suggested as the most effective disaccharide to preserve EVs during lyophilisation ( Chen et al, 2010 ; Bosch et al, 2016 ). This promising technique is an FDA-approved method for a range of proteins, liposomes and nanoparticles that enables their use in the pharmaceutical industry ( Van Backstal et al, 2017 ).…”

Section: Current Preservation Strategies For Evsmentioning

confidence: 99%

To Protect and to Preserve: Novel Preservation Strategies for Extracellular Vesicles

et al. 2018

View full text Add to dashboard Cite

Extracellular vesicles (EVs)-based therapeutics are based on the premise that EVs shed by stem cells exert similar therapeutic effects and these have been proposed as an alternative to cell therapies. EV-mediated delivery is an effective and efficient system of cell-to-cell communication which can confer therapeutic benefits to their target cells. EVs have been shown to promote tissue repair and regeneration in various animal models such as, wound healing, cardiac ischemia, diabetes, lung fibrosis, kidney injury, and many others. Given the unique attributes of EVs, considerable thought must be given to the preservation, formulation and cold chain strategies in order to effectively translate exciting preclinical observations to clinical and commercial success. This review summarizes current understanding around EV preservation, challenges in maintaining EV quality, and also bioengineering advances aimed at enhancing the long-term stability of EVs.

show abstract

Section: Current Preservation Strategies For Evsmentioning

confidence: 99%

To Protect and to Preserve: Novel Preservation Strategies for Extracellular Vesicles

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Journal of Nanomaterials adsorbed on the surface gradually merged into the core of the NPs, the composite reaction was completed, and the dispersion was gradually stabilized with the decreased PDI value. The zeta potential gradually changed from -15 to -0.307 mV, because the charge of HSA was -15 mV [36], whereas MTO-CHP NPs were almost uncharged, which further indicated a composite reaction between HSA and MTO-CHP NPs. The charge was redistributed by electrostatic interaction, and the absolute value of the overall potential decreased.…”

mentioning

confidence: 99%

Interaction of Mitoxantrone-Loaded Cholesterol Modified Pullulan Nanoparticles with Human Serum Albumin and Effect on Drug Release

Yuan

Guo

Zhong

et al. 2019

Journal of Nanomaterials

View full text Add to dashboard Cite

To clarify nanoparticle-protein interaction and their action characteristics, the interactions between MTO-CHP NPs and human serum albumin (HSA) were studied by isothermal titration calorimetry (ITC), fluorescence spectroscopy, dynamic light scattering (DLS), and circular dichroism spectroscopy (CD). Hydrophobically modified pullulan (CHP) nanoparticles (NPs) loaded with mitoxantrone (MTO) were prepared (MTO-CHP NPs) with size 166.9 nm. The spherical shape was verified by transmission electron microscopy (TEM). The ITC results demonstrated an interaction between MTO-CHP NPs mainly by hydrophobic interaction force, electrostatic force, and hydrogen bonding. The mean binding constant KA was 0.832×104 M−1 and mean HSA coverage 0.939±0.302. MTO-CHP NPs could quench the fluorescence intensity of HSA, which gradually decreased to be balanced in 9 h and indicated the completion of the complexation. The size and zeta potential changes of the combined particle were dynamically detected with DLS at 0, 3, 6, 9, 12, 15, and 18 h. When the reaction was completed at 9 h, the particle size and potential remained stable, accompanied by a size change from 89.91 to about 145 nm and potential change from -15 to -3 mV, respectively. The results of CD measurement showed that the change in ellipticity of HSA at 208 nm was similar to the fluorescence spectra and DLS measurements with MTO-CHP NPs combined with HSA. At the beginning of the reaction, the proportion of α-helix was 52.3% to 43.7%, which decreased by 39.1% at compound stabilization. The release of MTO from MTO-CHP NPs at pH=5.6 was significantly accelerated, whereas that of MTO from HSA-MTO-CHP NPs was significantly reduced, and the drug release was significantly slowed down even under acidic conditions, which indicates the beneficial effect of HSA on the persistence and stability of the HSA-MTO-CHP NP compound.

show abstract

“…Since HSA nanoparticles are barely cytotoxic, they can also be used as non-DNA carriers. For example, Redín et al developed HSA nanoparticles loaded with bevacizumab, a chemical drug used for treating cancers and a specific eye disease [ 52 ]. The payload of the nanoparticles generated using the desolvation method was improved by increasing antibody to albumin ratio to 0.15.…”

Section: Types Of Proteins Used To Produce Protein Nanoparticlesmentioning

confidence: 99%

Protein-Based Nanoparticles as Drug Delivery Systems

et al. 2020

View full text Add to dashboard Cite

Nanoparticles have been extensively used as carriers for the delivery of chemicals and biomolecular drugs, such as anticancer drugs and therapeutic proteins. Natural biomolecules, such as proteins, are an attractive alternative to synthetic polymers commonly used in nanoparticle formulation because of their safety. In general, protein nanoparticles offer many advantages, such as biocompatibility and biodegradability. Moreover, the preparation of protein nanoparticles and the corresponding encapsulation process involved mild conditions without the use of toxic chemicals or organic solvents. Protein nanoparticles can be generated using proteins, such as fibroins, albumin, gelatin, gliadine, legumin, 30Kc19, lipoprotein, and ferritin proteins, and are prepared through emulsion, electrospray, and desolvation methods. This review introduces the proteins used and methods used in generating protein nanoparticles and compares the corresponding advantages and disadvantages of each.

show abstract

Human serum albumin nanoparticles for ocular delivery of bevacizumab

Cited by 60 publications

References 47 publications

To Protect and to Preserve: Novel Preservation Strategies for Extracellular Vesicles

To Protect and to Preserve: Novel Preservation Strategies for Extracellular Vesicles

Interaction of Mitoxantrone-Loaded Cholesterol Modified Pullulan Nanoparticles with Human Serum Albumin and Effect on Drug Release

Protein-Based Nanoparticles as Drug Delivery Systems

Contact Info

Product

Resources

About